P/E ratio for FibroGen (FGEN)
P/E ratio as of April 2024 (TTM): -0.3451
According to FibroGen's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.345133. At the end of 2022 the company had a P/E ratio of -5.10.
P/E ratio history for FibroGen from 2014 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -5.10 | 13.62% |
| 2021 | -4.49 | -74.33% |
| 2020 | -17.5 | -64.1% |
| 2019 | -48.7 | 8.47% |
| 2018 | -44.9 | 45.03% |
| 2017 | -31.0 | 34.63% |
| 2016 | -23.0 | 7.24% |
| 2015 | -21.5 | 19.81% |
| 2014 | -17.9 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Illumina ILMN | -4.39 | 1,170.58% | 🇺🇸 USA |
 Acceleron Pharma XLRN | N/A | N/A | 🇺🇸 USA |
 Accelerate Diagnostics AXDX | -0.0978 | -71.65% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.